This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys
53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a
debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for
safety concerns just four months earlier.